President and Chief Executive Officer, Intellia Therapeutics
Appears in 1 story
Leading the HAELO readout and 2026 FDA submission
For decades, people with hereditary angioedema have lived with weekly injections, infusions, or pills to suppress unpredictable swelling attacks that can close off the airway. Intellia Therapeutics released topline data on April 27, 2026 from HAELO, a global Phase 3 trial of lonvoguran ziclumeran (lonvo-z) — the first late-stage clinical readout ever for an in-body CRISPR gene-editing therapy.
Updated 3 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
